Multivariate survival analysis
| Parameter . | Overall survival . | Event-free survival . | ||||
|---|---|---|---|---|---|---|
| Hazard ratio . | 95% CI . | P . | Hazard ratio . | 95% CI . | P . | |
| Cytogenetics | < .001 | < .001 | ||||
| High risk | 3.7 | 2.1-6.6 | < .001 | 2.7 | 1.6-4.6 | < .001 |
| FLT3-ITD mutation | 1.5 | 1.1-2.2. | .017 | 1.4 | 1.0-2.0 | .044 |
| CEBPα mutation | 0.3 | 0.1-0.7 | .005 | 0.3 | 0.1-0.7 | .003 |
| AES expression | 0.7 | 0.5-1.0 | .047 | 0.7 | 0.5-1.0 | .046 |
| Parameter . | Overall survival . | Event-free survival . | ||||
|---|---|---|---|---|---|---|
| Hazard ratio . | 95% CI . | P . | Hazard ratio . | 95% CI . | P . | |
| Cytogenetics | < .001 | < .001 | ||||
| High risk | 3.7 | 2.1-6.6 | < .001 | 2.7 | 1.6-4.6 | < .001 |
| FLT3-ITD mutation | 1.5 | 1.1-2.2. | .017 | 1.4 | 1.0-2.0 | .044 |
| CEBPα mutation | 0.3 | 0.1-0.7 | .005 | 0.3 | 0.1-0.7 | .003 |
| AES expression | 0.7 | 0.5-1.0 | .047 | 0.7 | 0.5-1.0 | .046 |
The mRNA expression values for AES were recorded as low or high with regard to median expression levels of all AML patients in the microarray study. Overall, 236 patients with available data were included in the multivariate analysis using a stepwise (forward) proportional Cox regression hazard model. The following parameters were included as categorical variables into the analysis: cytogenetics (3 groups: high risk, low risk, or intermediate/unknown), FLT3-TKD mutations, NRAS mutations, KRAS mutations, C/EBPα mutations, FLT3-ITD mutations, and AES expression levels as low/high according to the median expression.